Hipercol (Citicoline)

Hipercol is indicated for a range of neurological conditions in which cognitive performance is reduced or where support for brain repair is required, particularly in older adults and post‑stroke patients.

• Cognitive impairment associated with aging or mild neurodegenerative disease.
• Vascular dementia resulting from cerebrovascular insufficiency.
• Recovery of cognitive function after an ischemic or hemorrhagic stroke.
• Age‑related memory loss and attention deficits.
• Adjunctive support in patients undergoing neurorehabilitation programs.
• Cognitive decline related to traumatic brain injury.
• Support for patients with Parkinson’s disease experiencing mild cognitive deficits.

• Citicoline (CDP‑choline) is a nucleotide precursor that crosses the blood‑brain barrier and is metabolized to cytidine and choline. The choline moiety contributes to phosphatidylcholine synthesis, a major phospholipid of neuronal membranes, while the cytidine portion supports the formation of uridine triphosphate. Together they enhance acetylcholine production, improve membrane fluidity, and promote neuroprotective signaling pathways, thereby facilitating neuronal repair and functional recovery.

Adverse reactions to Hipercol are generally mild and transient, occurring in a minority of users; however, rare but serious events have been documented and should be monitored.

Common

• Headache
• Nausea or gastrointestinal discomfort
• Insomnia or mild sleep disturbance
• Dizziness or light‑headedness
• Transient increase in blood pressure
• Fatigue or mild weakness
• Dry mouth
• Transient visual disturbances
• Mild tremor
• Temporary loss of appetite
• Mild mood changes
• Brief episodes of confusion

Serious

• Allergic skin reactions such as rash or urticaria
• Severe hypotension or hypertensive crisis
• Hepatic enzyme elevation
• Acute neurological worsening (e.g., seizures)
• Cardiac arrhythmia
• Severe liver dysfunction
• Thromboembolic events
• Severe allergic anaphylaxis
• Acute renal failure
• Life‑threatening hemorrhage

When prescribing or using Hipercol, several precautionary measures should be considered to minimize risk and ensure appropriate patient selection.

• Assess liver and kidney function before initiating therapy.
• Use with caution in patients with uncontrolled hypertension.
• Monitor blood pressure regularly during treatment.
• Evaluate for history of seizures or epilepsy.
• Consider potential interactions with anticoagulant or antiplatelet agents.
• Avoid use during pregnancy or lactation unless benefits outweigh risks.
• Discontinue if severe adverse reactions occur.
• Review concomitant use of other cholinergic agents.
• Adjust dose in elderly patients with reduced metabolic capacity.

Hipercol may affect the pharmacokinetics or pharmacodynamics of several medicines; clinicians should review a patient’s medication list before starting therapy.

Avoid

• Concurrent use with high‑dose cholinergic agonists (e.g., donepezil) due to additive effects.
• Combination with potent anticoagulants (e.g., warfarin) that may increase bleeding risk.
• Co‑administration with MAO‑B inhibitors that could alter neurotransmitter balance.

Use with caution

• Concurrent antihypertensive agents; monitor blood pressure.
• Use with antiepileptic drugs; observe for seizure threshold changes.
• Combination with hepatotoxic medications; check liver enzymes.
• Concomitant use with drugs affecting platelet function (e.g., aspirin); assess bleeding risk.